Company profile
Sky Century Investment, Inc.
OTC: SKYI · Healthcare · Drug Manufacturers - Specialty & Generic
#1056 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
28DFH 41DQ 10GM —SS 27
v0.1 · 55/100 weight · provisional
↑ Piotroski F, revenue growth (YoY) · ↓ workforce scale, disclosure history
Methodology →Revenue TTM
$126.2k
Rev growth YoY (TTM)
+85.9%
Net income (FY)
-$117.2k
Employees
1
as of 2026-08-26
Market cap
$335.3k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$76.3k$76.3k2025
Net income-$117.2k-$117.2k2025
Operating income-$116.6k-$116.6k2025
Total assets$111.7k$111.7k2025
Liabilities$397.4k$397.4k2025
Equity-$285.7k-$285.7k2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Sky Century Investment, Inc.’s revenue?
Sky Century Investment, Inc. booked $76.3k in FY2025 revenue, growing 47% year over year — faster than most Healthcare companies we track, at a -153.6% net margin.
Peers · Healthcare
Imaging Dynamics Company Ltd.31DNemaura Medical Inc.——RegeneRx Biopharmaceuticals, Inc.——Aclarion, Inc.36DSilo Pharma, Inc.39DIMAC Holdings, Inc.——Neighbors
Clark →Key facts
CEONataliia Petranetska
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersLas Vegas, NV
ExchangeOTC: SKYI
Employees1
IPO date2014-11-03
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.